Midodrine in Hepatopulmonary Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 2, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Hepatopulmonary Syndrome (HPS)
Interventions
DRUG

Midodrine

Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER